- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03404817
Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations
This is a study of EMB-001 (a combination of two FDA-approved drugs, metyrapone and oxazepam) in healthy adults.This is a Phase 1, single dose, 3-period, 3-sequence, crossover study in 9 healthy male and female (not of childbearing potential) volunteers. The study will evaluate the bioavailability and food effect of a new formulation of EMB-001 relative to the original formulation of EMB 001.
During the study, a total of 9 eligible subjects will be randomized in a 1:1:1 ratio to each of 3 treatment sequences
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Long Beach, California, Estados Unidos, 90806
- Collaborative Neuroscience Network, LLC
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Provide written informed consent prior to any study procedures.
- Age 18 to 60 and able to read and write English
- Females must be of non-childbearing potential. Evidence of non-childbearing potential includes documented surgical sterilization (hysterectomy or bilateral oophorectomy) or being postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over age 45 in the absence of other biological or physiological cause. In addition, women must have a documented serum follicle stimulating hormone (FSH) level >40 mIU/mL.
- Light smokers (<10 cigarettes per day), non-smokers, or ex-smokers
- Body mass index ≥18.5 and <30 kg/m2
- Able to take oral medications and willing to adhere to medication regimen during the study
- No clinically relevant abnormal physical findings at the Screening examination
- Electrocardiogram without clinically significant abnormality at Screening
- Normal blood pressure (BP) and heart rate (systolic BP 90 to 140 mmHg; diastolic BP 50 to 90 mmHg; heart rate 50 to 100 beats per minute)
- No clinically relevant abnormal laboratory findings (general biochemistry, hematology, urinalysis, endocrinology [cortisol]) at Screening
Adequate organ function at screening as defined by:
- Serum aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN; unless the increased AST is assessed by the Investigator as due to hemolysis and/or hepatic iron deposition); and alanine aminotransferase (ALT) ≤ 2.5 × ULN (unless the increased ALT is assessed by the Investigator as due to hepatic iron deposition).
- Normal or elevated levels of serum bilirubin. Serum bilirubin >2× ULN is acceptable if the elevation is attributed to hemolysis with or without Gilbert's syndrome.
- Serum creatinine ≤ 1.25 × ULN. If serum creatinine > 1.25 × ULN, then 24-hour measured or calculated (Cockcroft-Gault) glomerular filtration rate ≥ 60 mL/min.
- Absolute neutrophil count (ANC) ≥ 1.2 × 109/L.
- Platelet count ≥ 100 × 109/L.
- Activated partial thromboplastin time (aPTT) and international normalized ratio ≤ 1.25 × ULN, unless the patient is receiving therapeutic anticoagulants.
Exclusion Criteria:
- Any significant current medical conditions (neurological, cardiovascular [including hypertension], endocrine, thyroid, renal, liver), seizures, delirium or hallucinations, or other unstable medical conditions
- Known hypersensitivity to or intolerance of oxazepam or metyrapone, or any benzodiazepine
- Subjects that have confounders of the levels of cortisol and/or cortisol binding globulin, including but not limited to: consuming estrogens, selective estrogen receptor modulators, or herbal/natural estrogen-like compounds; low serum albumin or total protein at screening; history of cirrhosis; hyperthyroidism; other thyroid disease that is untreated and not well-controlled; nephrotic syndrome or other protein-losing enteropathies.
- Current DSM-5 substance use disorder. Mild tobacco, marijuana, or alcohol use are allowed.
- Participants who have a positive test result at intake appointment on urine drug screens conducted for illicit drugs, including cannabis.
- Treatment with an investigational drug or biologic within the 30 days preceding the first dose of study medication or plans to take another investigational drug or biologic within 30 days of study completion (including the follow-up visit)
- Women of childbearing potential.
- Have positive serology test results at Screening for human immunodeficiency (HIV) 1/HIV 2 antibodies, Hepatitis B surface antigen (HBsAg) or Hepatitis C Antibody (HCVAb) before Day -2 of this study.
- Suicidal, homicidal thoughts and behaviors, or evidence of current severe mental illness such as schizophrenia, bipolar disorder or others that may interfere with subject safety or data integrity
- Use of serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor antidepressants in the 30 days prior to Period 1 or during the study.
- Use of any prescription, over-the-counter, or herbal medications, vitamins, or mineral supplements within 14 days prior to administration of their first study medication dose
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Sequence 1
Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows: Period 1: EMB-001 new formulation under fed condition Period 2: EMB-001 new formulation under fasted conditions Period 3: EMB-001 original formulation under fed conditions |
Single oral dose (720 mg metyrapone/24 mg oxazepam)
Single oral dose (720 mg metyrapone/24 mg oxazepam)
|
Comparador activo: Sequence 2
Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows: Period 1: EMB-001 original formulation under fed conditions Period 2: EMB-001 new formulation under fed conditions Period 3: EMB-001 new formulation under fasted conditions |
Single oral dose (720 mg metyrapone/24 mg oxazepam)
Single oral dose (720 mg metyrapone/24 mg oxazepam)
|
Comparador activo: Sequence 3
Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows: Period 1: EMB-001 new formulation under fasted conditions Period 2: EMB-001 original formulation under fed conditions Period 3: EMB-001 new formulation under fed conditions |
Single oral dose (720 mg metyrapone/24 mg oxazepam)
Single oral dose (720 mg metyrapone/24 mg oxazepam)
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of EMB-001
Periodo de tiempo: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post drug administration in each Period.
|
The AUC0-inf is calculated in a plot of concentration of drug in blood plasma against time and extrapolated to infinity.
|
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post drug administration in each Period.
|
Maximum Observed Concentration (Cmax) of EMB-001
Periodo de tiempo: Periods 1-3, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post drug administration in each Period.
|
Cmax is the maximum observed concentration of drug in blood plasma.
|
Periods 1-3, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post drug administration in each Period.
|
Time to Maximum Concentration (Tmax) of EMB-001
Periodo de tiempo: Periods 1-3, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post drug administration in each Period.
|
Tmax is the time elapsed from the time of drug administration to maximum plasma concentration.
|
Periods 1-3, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post drug administration in each Period.
|
Apparent Half-Life (t1/2) of EMB-001
Periodo de tiempo: Periods 1-3, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post drug administration in each Period.
|
Half-life is defined as the time required for the drug plasma concentration to be reduced to half.
|
Periods 1-3, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post drug administration in each Period.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Periodo de tiempo: 21 days
|
Adverse event data (including clinically significant changes in laboratory values) will be compiled for EMB-001.
|
21 days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Mike Detke, MD, Embera NeuroTherapeutics, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- ERL-PK001
- U01DA038879 (NIH)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Trastorno por consumo de cocaína
-
Nanfang Hospital of Southern Medical UniversityShenzhen People's Hospital; Second Affiliated Hospital of Guangzhou Medical UniversityAún no reclutandoLesiones Pancreáticas Sólidas | USE-FNB
-
Asan Medical CenterDesconocidoUSE-PAAF | CitodiagnósticoCorea, república de
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)Activo, no reclutandoQuiste pancreático | USE-PAAFEstados Unidos
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityTerminadoCáncer de recto | USE-PAAF | Pathological Complete RemissionPorcelana
-
National Cheng-Kung University HospitalDesconocidoMétodo de succión húmeda basado en heparina en EUS Biopsia con aguja fina de masa pancreática sólidaNeoplasias pancreáticas | Ultrasonografía endoscópica | USE-PAAFTaiwán
Ensayos clínicos sobre Original formulation EMB-001
-
Embera NeuroTherapeutics, Inc.National Institute on Drug Abuse (NIDA)TerminadoTrastorno por consumo de cocaínaEstados Unidos
-
Embera NeuroTherapeutics, Inc.Rose Research Center, LLC; Segal Trials; Foundation for a Smoke Free World INCTerminadoTrastorno por consumo de tabacoEstados Unidos
-
Bond BiosciencesTerminadoHemocromatosis HereditariaAustralia
-
Embera NeuroTherapeutics, Inc.National Institute on Drug Abuse (NIDA)TerminadoTrastorno por consumo de cocaínaEstados Unidos